Maprotiline
Psychosomatic Disorders
Hannover Medical SchoolSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Psychosomatic Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Hannover Medical School | Phase 3 | B |
Oxcarbamezapine Hannover Medical School | Phase 3 | B |
Acamprosate Hannover Medical School | Phase 3 | B |
LAMOTRIGINE Hannover Medical School | Phase 3 | B |
Pregabalin Hannover Medical School | Phase 3 | B |
View all 50 →
Same molecule, other indications
Maprotiline is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →